173 related articles for article (PubMed ID: 10589280)
1. [Minimal residual disease. Methodologies and clinical implications].
Ortega M; Coll MD; Solé F; Caballín MR
Sangre (Barc); 1999 Aug; 44(4):283-90. PubMed ID: 10589280
[No Abstract] [Full Text] [Related]
2. Minimal residual disease in hematologic malignancies.
San-Miguel JF; Bartram C; Campana D; Andreeff M
Rev Invest Clin; 1994 Apr; Suppl():147-52. PubMed ID: 7886299
[No Abstract] [Full Text] [Related]
3. Detection of recurrent translocations using real time PCR; assessment of the technique for diagnosis and detection of minimal residual disease.
Gabert J
Haematologica; 1999 Jun; 84 Suppl EHA-4():107-9. PubMed ID: 10907485
[No Abstract] [Full Text] [Related]
4. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
[TBL] [Abstract][Full Text] [Related]
5. Investigation of minimal residual disease in adult Ph1 positive acute lymphoblastic leukemia by a combination of cell sorting and fluorescence in situ hybridization: a preliminary study on 6 cases.
Cambier N; Soenen-Cornu V; Laï JL; Cosson A; Fenaux P; Preudhomme C
Haematologica; 2000 Jun; 85(6):664-5. PubMed ID: 10870127
[No Abstract] [Full Text] [Related]
6. [A minimal residual population of leukemic cells in patients with acute myeloid leukemias].
Gal'tseva IV; Parovichnikova EN; Savchenko VG
Ter Arkh; 1997; 69(7):74-9. PubMed ID: 9424769
[No Abstract] [Full Text] [Related]
7. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
8. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
9. Combined cell sorting and FISH for detection of minimal residual disease in bone marrow of children with acute leukemia or solid tumors.
Sainati L; Spinelli M; Leszl A; Cocito MG; Stella M; Basso G
Eur J Histochem; 1997; 41 Suppl 2():167-8. PubMed ID: 9859833
[No Abstract] [Full Text] [Related]
10. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.
Sausville JE; Salloum RG; Sorbara L; Kingma DW; Raffeld M; Kreitman RJ; Imus PD; Venzon D; Stetler-Stevenson M
Am J Clin Pathol; 2003 Feb; 119(2):213-7. PubMed ID: 12579991
[TBL] [Abstract][Full Text] [Related]
11. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
Chen JS; Hsiao CC; Sheen JM; Cheng CN
Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
[TBL] [Abstract][Full Text] [Related]
12. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
Zwick D; Cooley L; Hetherington M
Lab Hematol; 2006; 12(2):75-81. PubMed ID: 16751134
[TBL] [Abstract][Full Text] [Related]
13. [Spectral karyotyping (SKY) principle, avantages and limitations].
Belaud-Rotureau MA; Elghezal H; Bernardin C; Sanlaville D; Radford-Weiss I; Raoul O; Vekemans M; Romana SP
Ann Biol Clin (Paris); 2003; 61(2):139-46. PubMed ID: 12702468
[TBL] [Abstract][Full Text] [Related]
14. [Minimal residual disease in hematology].
Rák K
Orv Hetil; 2001 May; 142(21):1091-5. PubMed ID: 11449837
[No Abstract] [Full Text] [Related]
15. Monitoring minimal residual disease in pediatric hematologic malignancies.
Campana D
Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
[No Abstract] [Full Text] [Related]
16. [Chromosome analysis of and genetic testing for myeloid leukemia].
Yokota H; Yatomi Y
Nihon Rinsho; 2009 Oct; 67(10):1911-5. PubMed ID: 19860189
[TBL] [Abstract][Full Text] [Related]
17. Biphenotypic acute leukemia with t(15;17).
Scolnik MP; Aranguren PN; Cuello MT; Palacios MF; Sanjurjo J; Giunta M; Bracco MM; Acevedo S
Leuk Lymphoma; 2005 Apr; 46(4):607-10. PubMed ID: 16019491
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-positive blastic plasmacytoid dendritic cell leukemia.
Adams RL; McCarthy C; Bird RJ
Cancer Genet Cytogenet; 2009 Dec; 195(2):186-8. PubMed ID: 19963123
[No Abstract] [Full Text] [Related]
19. [Minimal residual disease in childhood acute leukemias].
Pawińska K; Balwierz W; Baran J
Przegl Lek; 2006; 63(1):41-3. PubMed ID: 16892899
[TBL] [Abstract][Full Text] [Related]
20. [Applications of fluorescence in situ hybridization in the study of hematologic neoplasms].
Hernández JM; Tabernero MD; García JL
Sangre (Barc); 1996 Aug; 41(4):305-9. PubMed ID: 8984672
[No Abstract] [Full Text] [Related]
[Next] [New Search]
